Adagio Medical (ADGM) CFO discloses 15,000-share insider stock purchase

Rhea-AI Filing Summary

Adagio Medical Holdings, Inc. reported an open market share purchase by its Chief Financial Officer, Deborah Kaster. On 12/16/2025, she bought 15,000 shares of common stock at a weighted average price of $1.1982 per share, and now beneficially owns 15,000 shares directly. The transaction was carried out in multiple trades, with prices ranging from $1.11 to $1.20 per share, and was reported as a purchase under the company’s insider reporting obligations.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kaster Deborah

(Last) (First) (Middle)

C/O ADAGIO MEDICAL HOLDINGS, INC.

26051 MERIT CIRCLE, SUITE 102

(Street)

LAGUNA HILLS CA 92653

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Adagio Medical Holdings, Inc. [ ADGM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/16/2025		P(1)		15,000	A	$1.1982(2)	15,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Open market purchase.

2. This transaction was executed in multiple trades at prices ranging from $1.11 to $1.20. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

	/s/ Deborah Kaster	12/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Adagio Medical Holdings (ADGM) disclose?

Adagio Medical Holdings disclosed that its Chief Financial Officer, Deborah Kaster, purchased 15,000 shares of the company’s common stock in an open market transaction.

At what price did the ADGM CFO buy shares in this insider trade?

The CFO’s purchase had a weighted average price of $1.1982 per share, with individual trades executed in a price range from $1.11 to $1.20 per share.

When did the Adagio Medical (ADGM) insider share purchase occur?

The reported open market purchase by the CFO took place on 12/16/2025, with the related ownership report signed on 12/18/2025.

How many Adagio Medical (ADGM) shares does the CFO own after the transaction?

Following the reported transaction, Chief Financial Officer Deborah Kaster beneficially owns 15,000 shares of Adagio Medical Holdings common stock directly.

What does it mean that the ADGM CFO’s trade was described as an open market purchase?

The filing explains that the transaction was an open market purchase, meaning the CFO bought the 15,000 shares through regular market trading rather than via a private agreement or option exercise.

Was the Adagio Medical (ADGM) insider trade executed in multiple transactions?

Yes. The report notes that the 15,000 shares were acquired in multiple trades at prices ranging from $1.11 to $1.20, and the reported price is the weighted average of those trades.